A detailed history of 626 Financial, LLC transactions in Bristol Myers Squibb CO stock. As of the latest transaction made, 626 Financial, LLC holds 9,354 shares of BMY stock, worth $544,683. This represents 0.27% of its overall portfolio holdings.

Number of Shares
9,354
Previous 9,414 0.64%
Holding current value
$544,683
Previous $390,000 24.1%
% of portfolio
0.27%
Previous 0.23%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 15, 2024

SELL
$39.66 - $51.75 $2,379 - $3,105
-60 Reduced 0.64%
9,354 $484,000
Q2 2024

Jul 12, 2024

SELL
$40.25 - $52.99 $15,093 - $19,871
-375 Reduced 3.83%
9,414 $390,000
Q1 2024

Apr 18, 2024

SELL
$47.98 - $54.4 $42,030 - $47,654
-876 Reduced 8.21%
9,789 $530,000
Q4 2023

Jan 11, 2024

SELL
$48.48 - $57.85 $1,939 - $2,314
-40 Reduced 0.37%
10,665 $547,000
Q3 2023

Oct 11, 2023

SELL
$57.89 - $64.73 $14,414 - $16,117
-249 Reduced 2.27%
10,705 $621,000
Q2 2023

Jul 14, 2023

SELL
$63.71 - $70.74 $13,888 - $15,421
-218 Reduced 1.95%
10,954 $700,000
Q1 2023

Apr 12, 2023

SELL
$65.71 - $74.53 $5,716 - $6,484
-87 Reduced 0.77%
11,172 $774,000
Q4 2022

Jan 24, 2023

BUY
$68.48 - $81.09 $753 - $891
11 Added 0.1%
11,259 $0
Q3 2022

Oct 21, 2022

BUY
$0.13 - $76.84 $1 - $845
11 Added 0.1%
11,248 $800,000
Q2 2022

Jul 12, 2022

BUY
$72.62 - $79.98 $798 - $879
11 Added 0.1%
11,237 $864,000
Q1 2022

May 05, 2022

SELL
$61.48 - $73.72 $8,668 - $10,394
-141 Reduced 1.24%
11,226 $820,000
Q4 2021

Feb 14, 2022

BUY
$53.63 - $62.52 $7,561 - $8,815
141 Added 1.26%
11,367 $709,000
Q1 2021

Apr 14, 2022

BUY
$59.34 - $66.74 $666,150 - $749,223
11,226 New
11,226 $820,000

Others Institutions Holding BMY

About BRISTOL MYERS SQUIBB CO


  • Ticker BMY
  • Exchange NYSE
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 2,126,160,000
  • Market Cap $124B
  • Description
  • Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple my...
More about BMY
Track This Portfolio

Track 626 Financial, LLC Portfolio

Follow 626 Financial, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of 626 Financial, LLC, based on Form 13F filings with the SEC.

News

Stay updated on 626 Financial, LLC with notifications on news.